

# Raquel Sanchez-Valle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1317273/publications.pdf>

Version: 2024-02-01

277  
papers

12,461  
citations

31976

53  
h-index

37204

96  
g-index

313  
all docs

313  
docs citations

313  
times ranked

13279  
citing authors

#	ARTICLE	IF	CITATIONS
1	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
2	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 443-453.	10.2	602
3	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014, 6, 243ra86.	12.4	600
4	Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. <i>PLoS ONE</i> , 2014, 9, e89741.	2.5	407
5	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476.	6.9	392
6	Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. <i>Neurology</i> , 2003, 60, 230-234.	1.1	297
7	A Pan-European Study of the <i>C9orf72</i> Repeat Associated with <scp>FTLD</scp>: Geographic Prevalence, Genomic Instability, and Intermediate Repeats. <i>Human Mutation</i> , 2013, 34, 363-373.	2.5	247
8	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 623-636.	3.7	207
9	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. <i>Neurobiology of Aging</i> , 2010, 31, 725-731.	3.1	196
10	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	30.7	182
11	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.2	175
12	Detection of $\beta$ -synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study. <i>Lancet Neurology</i> , The, 2021, 20, 203-212.	10.2	174
13	Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2013, 74, 655-668.	5.3	171
14	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2017, 82, 419-428.	5.3	161
15	YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. <i>Molecular Neurodegeneration</i> , 2017, 12, 83.	10.8	140
16	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
17	Increased Cortical Thickness and Caudate Volume Precede Atrophy in PSEN1 Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 909-922.	2.6	136
18	Cognitive reserve modulates task-induced activations and deactivations in healthy elders, amnesic mild cognitive impairment and mild Alzheimer's disease. <i>Cortex</i> , 2010, 46, 451-461.	2.4	136

#	ARTICLE	IF	CITATIONS
19	Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years. <i>Brain</i> , 2012, 135, 3051-3061.	7.6	135
20	Prevalence of amyloid $\beta$ pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	5.3	132
21	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	10.2	128
22	Screening for amnesic mild cognitive impairment and early Alzheimer's disease with M@T (Memory) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 294-304.	2.7	124
23	Clinical features and <i>APOE</i> genotype of pathologically proven early-onset Alzheimer disease. <i>Neurology</i> , 2011, 76, 1720-1725.	1.1	123
24	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. <i>Acta Neuropathologica</i> , 2014, 127, 407-418.	7.7	123
25	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. <i>Molecular Neurobiology</i> , 2017, 54, 5550-5562.	4.0	119
26	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 546-560.	3.8	115
27	LifeTime and improving European healthcare through cell-based interceptive medicine. <i>Nature</i> , 2020, 587, 377-386.	27.8	108
28	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 263-270.	1.9	106
29	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2013, 125, 201-213.	7.7	103
30	Cerebrospinal Fluid Level of YKL-40 Protein in Preclinical and Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 901-908.	2.6	102
31	Active A $\beta$ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 10-22.	3.7	102
32	CSF sAPP $\beta$ , YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , 2017, 89, 178-188.	1.1	100
33	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Human Molecular Genetics</i> , 2014, 23, 749-754.	2.9	98
34	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	10.2	97
35	Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid A $\beta$ -Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas. <i>Biological Psychiatry</i> , 2011, 70, 183-190.	1.3	93
36	Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. <i>Acta Neuropathologica</i> , 2014, 128, 397-410.	7.7	93

#	ARTICLE	IF	CITATIONS
37	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. <i>Neurobiology of Aging</i> , 2014, 35, 444.e1-444.e4.	3.1	92
38	A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 1772-1778.	3.1	87
39	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	2.5	87
40	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1259-1272.	0.8	86
41	Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190.	2.4	84
42	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016, 132, 213-224.	7.7	83
43	Interactions of cognitive reserve with regional brain anatomy and brain function during a working memory task in healthy elders. <i>Biological Psychology</i> , 2009, 80, 256-259.	2.2	81
44	Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic. <i>Molecular Neurobiology</i> , 2016, 53, 2189-2199.	4.0	80
45	Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies. <i>Journal of Neurology</i> , 2009, 256, 1620-1628.	3.6	77
46	Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. <i>Journal of Neurology</i> , 2007, 254, 901-906.	3.6	72
47	14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. <i>Neurology</i> , 2001, 57, 722-724.	1.1	68
48	Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 319-326.	2.6	66
49	CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies. <i>European Journal of Neurology</i> , 2007, 14, 121-124.	3.3	61
50	Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases. <i>Alzheimer's and Dementia</i> , 2018, 14, 751-763.	0.8	61
51	Effects of <i>IgLON5</i> Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration. <i>Annals of Neurology</i> , 2020, 88, 1023-1027.	5.3	61
52	Distinct Functional Activity of the Precuneus and Posterior Cingulate Cortex During Encoding in the Preclinical Stage of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 517-526.	2.6	59
53	Determination of Neuronal Antibodies in Suspected and Definite Creutzfeldt-Jakob Disease. <i>JAMA Neurology</i> , 2014, 71, 74.	9.0	59
54	CSF Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis Predict Long-Term Outcome. <i>Frontiers in Immunology</i> , 2022, 13, 866153.	4.8	57

#	ARTICLE	IF	CITATIONS
55	Analysis of the <i>CHCHD10</i> gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. <i>Brain</i> , 2015, 138, e400-e400.	7.6	56
56	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 684-691.	1.9	55
57	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 612-621.	1.9	55
58	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. <i>Neurobiology of Aging</i> , 2016, 38, 47-55.	3.1	54
59	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 113.	6.2	54
60	Neuroimaging and Biochemical Markers in the Three Variants of Primary Progressive Aphasia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013, 35, 106-117.	1.5	53
61	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017, 134, 475-487.	7.7	53
62	Clinical, Neuropathologic, and Biochemical Profile of the Amyloid Precursor Protein I716F Mutation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 53-59.	1.7	52
63	Presentations and mechanisms of CNS disorders related to COVID-19. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	52
64	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. <i>Neurology</i> , 2021, 96, e2296-e2312.	1.1	52
65	Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. <i>Journal of Neural Transmission</i> , 2011, 118, 259-262.	2.8	49
66	Poly(GP), neurofilament and grey matter deficits in <i>C9orf72</i> expansion carriers. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 583-597.	3.7	48
67	<i>TARDBP</i> mutation p.L383V associated with semantic dementia and complex proteinopathy. <i>Neuropathology and Applied Neurobiology</i> , 2014, 40, 225-230.	3.2	48
68	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1251-1260.	0.8	47
69	Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias. <i>Alzheimer's and Dementia</i> , 2020, 16, 262-272.	0.8	47
70	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017, 54, 6647-6654.	4.0	45
71	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019, 142, 1121-1133.	7.6	45
72	Neuronal intranuclear (hyaline) inclusion disease and fragile X-associated tremor/ataxia syndrome: a morphological and molecular dilemma. <i>Brain</i> , 2017, 140, e51-e51.	7.6	43

#	ARTICLE	IF	CITATIONS
73	Longitudinal Study of Amnesic Patients at High Risk for Alzheimer's Disease: Clinical, Neuropsychological and Magnetic Resonance Spectroscopy Features. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 402-410.	1.5	42
74	Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 698-707.	3.7	42
75	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	5.9	42
76	Cortical Brain Metabolism as Measured by Proton Spectroscopy Is Related to Memory Performance in Patients with Amnesic Mild Cognitive Impairment and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 274-279.	1.5	41
77	Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. <i>Journal of Neurology</i> , 2008, 255, 488-494.	3.6	40
78	Rapidly Progressive Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 267-271.	1.3	40
79	Cognitive Reserve Proxies Relate to Gray Matter Loss in Cognitively Healthy Elderly with Abnormal Cerebrospinal Fluid Amyloid- $\beta$ Levels. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 715-726.	2.6	40
80	Donepezil Treatment Stabilizes Functional Connectivity During Resting State and Brain Activity During Memory Encoding in Alzheimer's Disease. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 199-205.	1.4	40
81	The memory alteration test (M@T) discriminates between subjective memory complaints, mild cognitive impairment and Alzheimer's disease. <i>Archives of Gerontology and Geriatrics</i> , 2010, 50, 171-174.	3.0	38
82	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 127-134.	2.7	38
83	Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2002, 73, 79-81.	1.9	37
84	Challenges associated with biomarker-based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 346-357.	2.4	37
85	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Neurodegenerative Diseases</i> , 2016, 16, 69-76.	1.4	36
86	The APOE $\epsilon$ 4 genotype modulates CSF YKL40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 50-59.	2.4	36
87	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.8	36
88	Clinicopathological Correlations and Concomitant Pathologies in Rapidly Progressive Dementia: A Brain Bank Series. <i>Neurodegenerative Diseases</i> , 2015, 15, 350-360.	1.4	35
89	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 87, 139.e1-139.e7.	3.1	35
90	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	3.1	34

#	ARTICLE	IF	CITATIONS
91	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015, 36, 2005.e15-2005.e22.	3.1	34
92	Validation of Î±-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease. <i>Molecular Neurobiology</i> , 2018, 55, 2249-2257.	4.0	34
93	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, 1329-1341.	0.8	34
94	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	4.2	33
95	Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 919-927.	2.6	32
96	Serum Progranulin Levels in Patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease: Detection of GRN Mutations in a Spanish Cohort. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 581-591.	2.6	31
97	Frontotemporal Dementia Caused by the P301L Mutation in <i>MAPT</i> Gene: Clinicopathological Features of 13 Cases from the Same Geographical Origin in Barcelona, Spain. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 213-221.	1.5	31
98	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. <i>Alzheimer's and Dementia</i> , 2021, 17, 969-983.	0.8	31
99	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
100	14-3-3 protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease. <i>Neuroscience Letters</i> , 2002, 320, 69-72.	2.1	30
101	Neuropsychological profile of prodromal Alzheimer's disease (Prd-AD) and their radiological correlates. <i>Archives of Gerontology and Geriatrics</i> , 2011, 52, 190-196.	3.0	30
102	Evolving brain structural changes in PSEN1 mutation carriers. <i>Neurobiology of Aging</i> , 2015, 36, 1261-1270.	3.1	30
103	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. <i>Sleep</i> , 2019, 42, .	1.1	30
104	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. <i>Brain</i> , 2023, 146, 321-336.	7.6	30
105	Clinical and genetic features of human prion diseases in Catalonia: 1993-2002. <i>European Journal of Neurology</i> , 2004, 11, 649-655.	3.3	29
106	Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment. <i>NeuroImage: Clinical</i> , 2019, 23, 101927.	2.7	29
107	Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101777.	2.7	29
108	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. <i>Alzheimer's and Dementia</i> , 2020, 16, 292-304.	0.8	29



#	ARTICLE	IF	CITATIONS
109	Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	29
110	Characterizing the Clinical Features and Atrophy Patterns of <i>MAPT</i> -Related Frontotemporal Dementia With Disease Progression Modeling. <i>Neurology</i> , 2021, 97, e941-e952.	1.1	29
111	CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. <i>Journal of Neurology</i> , 2004, 251, 1278-1279.	3.6	28
112	PICOGEN: experiencia de 5 años de un programa de asesoramiento genético en demencia. <i>Neurología</i> , 2011, 26, 143-149.	0.7	28
113	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017, 7, 2477.	3.3	28
114	Digital biomarker-based individualized prognosis for people at risk of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12073.	2.4	28
115	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28
116	Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021, 32, 102804.	2.7	28
117	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27
118	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.8	27
119	Modelling the cascade of biomarker changes in <i>GRN</i> -related frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 494-501.	1.9	27
120	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	7.6	27
121	Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimer's Disease Patients Alter Calcium Homeostasis. <i>PLoS ONE</i> , 2013, 8, e74203.	2.5	26
122	Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria (FTDC) in a clinicopathological cohort. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 882-892.	3.2	26
123	CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals. <i>NeuroImage: Clinical</i> , 2019, 23, 101801.	2.7	26
124	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	2.4	26
125	From Progressive Nonfluent Aphasia to Corticobasal Syndrome: A Case Report of Corticobasal Degeneration. <i>Neurocase</i> , 2006, 12, 355-359.	0.6	25
126	Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid- $\beta^2$ and Tau. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1575-1587.	2.6	25



#	ARTICLE	IF	CITATIONS
127	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 975-984.	1.9	25
128	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease Families with PSEN1 Mutations. <i>Neurodegenerative Diseases</i> , 2011, 8, 202-207.	1.4	24
129	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.8	24
130	A novel mutation in the PSEN1 gene (L286P) associated with familial early-onset dementia of Alzheimer type and lobar haematomas. <i>European Journal of Neurology</i> , 2007, 14, 1409-1412.	3.3	23
131	Voxel based morphometry features and follow-up of amnesic patients at high risk for Alzheimer's disease conversion. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 875-884.	2.7	23
132	Rare Variants in PLD3 Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. <i>Human Mutation</i> , 2015, 36, 1226-1235.	2.5	23
133	Education modulates brain maintenance in presymptomatic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1124-1130.	1.9	23
134	Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures. <i>Human Brain Mapping</i> , 2020, 41, 2004-2013.	3.6	22
135	A novel PSEN1 mutation (K239N) associated with Alzheimer's disease with wide range age of onset and slow progression. <i>European Journal of Neurology</i> , 2010, 17, 994-996.	3.3	21
136	Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias. <i>Acta Neuropathologica Communications</i> , 2018, 6, 41.	5.2	21
137	The hippocampal longitudinal axis's relevance for underlying tau and TDP-43 pathology. <i>Neurobiology of Aging</i> , 2018, 70, 1-9.	3.1	21
138	Neuroanatomical and cognitive correlates of visual hallucinations in Parkinson's disease and dementia with Lewy bodies: Voxel-based morphometry and neuropsychological meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 367-382.	6.1	21
139	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	5.3	21
140	Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases. <i>Molecular Neurobiology</i> , 2019, 56, 2811-2821.	4.0	20
141	Clinical applicability of diagnostic biomarkers in early-onset cognitive impairment. <i>European Journal of Neurology</i> , 2019, 26, 1098-1104.	3.3	20
142	Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 94.	6.2	20
143	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. <i>Brain Communications</i> , 2020, 2, .	3.3	20
144	Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. <i>Psychiatry Research - Neuroimaging</i> , 2011, 192, 140-146.	1.8	19

#	ARTICLE	IF	CITATIONS
145	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 66, 181.e3-181.e10.	3.1	19
146	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 997-1004.	1.9	19
147	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. <i>Annals of Neurology</i> , 2020, 88, 113-122.	5.3	19
148	Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1456-1470.	3.7	19
149	Evolving Brain Functional Abnormalities in PSEN1 Mutation Carriers: A Resting and Visual Encoding fMRI Study. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 165-175.	2.6	19
150	Distinctive age-related temporal cortical thinning in asymptomatic granulin gene mutation carriers. <i>Neurobiology of Aging</i> , 2013, 34, 1462-1468.	3.1	18
151	Alpha-synuclein Aggregates in Labial Salivary Glands of Idiopathic Rapid Eye Movement Sleep Behavior Disorder. <i>Sleep</i> , 2018, 41, .	1.1	18
152	Systematic Screening of Ubiquitin/p62 Aggregates in Cerebellar Cortex Expands the Neuropathological Phenotype of the C9orf72 Expansion Mutation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 703-709.	1.7	18
153	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	1.2	18
154	TREM2 expression in the brain and biological fluids in prion diseases. <i>Acta Neuropathologica</i> , 2021, 141, 841-859.	7.7	18
155	The amyloid- $\beta$ isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. <i>Molecular Medicine Reports</i> , 2012, 5, 1111-1115.	2.4	17
156	Preclinical MSA in definite Creutzfeldt-Jakob disease. <i>Neuropathology</i> , 2012, 32, 158-163.	1.2	17
157	Quantitative Magnetic Resonance Abnormalities in Creutzfeldt-Jakob Disease and Fatal Insomnia. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 431-443.	2.6	17
158	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 827-835.	2.6	17
159	A novel <i>MAPT</i> mutation (P301T) associated with familial frontotemporal dementia. <i>European Journal of Neurology</i> , 2007, 14, e9-10.	3.3	16
160	Molecular evidence of founder effects of fatal familial insomnia through SNP haplotypes around the D178N mutation. <i>Neurogenetics</i> , 2008, 9, 109-118.	1.4	16
161	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. <i>Neurobiology of Aging</i> , 2018, 62, 245.e1-245.e7.	3.1	16
162	Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases. <i>Brain</i> , 2022, 145, 700-712.	7.6	16

#	ARTICLE	IF	CITATIONS
163	A neurodegenerative disease landscape of rare mutations in Colombia due to founder effects. <i>Genome Medicine</i> , 2022, 14, 27.	8.2	16
164	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 5902-5911.	4.0	15
165	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018, 69, 293.e9-293.e11.	3.1	15
166	MAPT gene duplications are not a cause of frontotemporal lobar degeneration. <i>Neuroscience Letters</i> , 2007, 424, 61-65.	2.1	14
167	Analysis of the exon 1 polymorphism in the Tau gene in transmissible spongiform encephalopathies. <i>Journal of Neurology</i> , 2002, 249, 938-939.	3.6	13
168	Late-onset frontotemporal dementia associated with a novel PGRN mutation. <i>Journal of Neural Transmission</i> , 2007, 114, 1051-1054.	2.8	13
169	A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 2011, 496, 40-42.	2.1	13
170	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2518-2530.	3.7	13
171	Naming Is Associated with Left Temporal Pole Metabolite Levels in Neurodegenerative Diseases. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 212-217.	1.5	12
172	Identifying Earlier Alzheimer's Disease: Insights from the Preclinical and Prodromal Phases. <i>Neurodegenerative Diseases</i> , 2012, 10, 158-160.	1.4	12
173	Large APP locus duplication in a sporadic case of cerebral haemorrhage. <i>Neurogenetics</i> , 2014, 15, 145-149.	1.4	12
174	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid- $\beta^2$ positivity. <i>Cortex</i> , 2019, 121, 117-124.	2.4	12
175	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in <i>C9orf72</i> expansion carriers in the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1325-1328.	1.9	12
176	Diagnostic Accuracy of MRI Visual Rating Scales in the Diagnosis of Early Onset Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1575-1583.	2.6	12
177	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. <i>JAMA Network Open</i> , 2021, 4, e211290.	5.9	12
178	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	6.2	12
179	Development of a sensitive trial-ready poly(GP) CSF biomarker assay for <i>C9orf72</i> -associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 761-771.	1.9	12
180	First demonstrated de novo insertion in the prion protein gene in a young patient with dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 845-846.	1.9	11

#	ARTICLE	IF	CITATIONS
181	Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia. <i>European Journal of Neurology</i> , 2013, 20, 1459.	3.3	11
182	Sporadic MM2-thalamic+cortical Creutzfeldt-Jakob disease: Utility of diffusion tensor imaging in the detection of cortical involvement <i>in vivo</i> . <i>Neuropathology</i> , 2016, 36, 199-204.	1.2	11
183	Screening of dementia genes by whole-exome sequencing in Spanish patients with early-onset dementia: likely pathogenic, uncertain significance and risk variants. <i>Neurobiology of Aging</i> , 2020, 93, e1-e9.	3.1	11
184	PICOGEN: Five years experience with a genetic counselling program for dementia. <i>Neurología (English)</i> 2020, 31, 100-104.	0.4	10
185	Breakpoint Sequence Analysis of an A $\beta$ 2PP Locus Duplication Associated with Autosomal Dominant Alzheimer's Disease and Severe Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 303-308.	2.6	10
186	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	2.6	10
187	Variably protease-sensitive prionopathy presenting within ALS/FTD spectrum. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1297-1302.	3.7	10
188	Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 211-225.	2.6	10
189	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 608-616.	1.9	10
190	Cortical microstructure in primary progressive aphasia: a multicenter study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 27.	6.2	10
191	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 66.	10.8	9
192	Assessing the role of TUBA4A gene in frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2016, 38, 215.e13-215.e14.	3.1	9
193	Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants. <i>Brain Pathology</i> , 2021, 31, e12942.	4.1	9
194	Microglial Hyperreactivity Evolved to Immunosuppression in the Hippocampus of a Mouse Model of Accelerated Aging and Alzheimer's Disease Traits. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 622360.	3.4	9
195	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	10.8	9
196	Inherited prion disease with 4-octapeptide repeat insertion linked to valine at codon 129. <i>Brain</i> , 2012, 135, e212-e212.	7.6	8
197	Hirano body-rich subtypes of Creutzfeldt-Jakob disease. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 153-161.	3.2	8
198	Atypical neuropathological sCJD-MM phenotype with abundant white matter Kuru-type plaques sparing the cerebellar cortex. <i>Neuropathology</i> , 2013, 33, 204-208.	1.2	8

#	ARTICLE	IF	CITATIONS
199	Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients. <i>Biomolecules</i> , 2019, 9, 800.	4.0	8
200	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021, 99, 99.e15-99.e22.	3.1	8
201	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021, 103, 158.e1-158.e5.	3.1	8
202	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	2.7	8
203	Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 176.	6.2	8
204	Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 243-252.	3.2	8
205	Ancestral origins of the prion protein gene D178N mutation in the Basque Country. <i>Human Genetics</i> , 2005, 117, 61-69.	3.8	7
206	A unique common ancestor introduced P301L mutation in MAPT gene in frontotemporal dementia patients from Barcelona (Baix Llobregat, Spain). <i>Neurobiology of Aging</i> , 2019, 84, 236.e9-236.e15.	3.1	7
207	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTL D cohorts. <i>Neurology</i> , 2020, 95, e3288-e3302.	1.1	7
208	Autoantibodies against the prion protein in individuals with PRNP mutations. <i>Neurology</i> , 2020, 95, e2028-e2037.	1.1	7
209	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168.	1.9	7
210	SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration. <i>Brain</i> , 2021, 144, 2798-2811.	7.6	7
211	Accelerated long-term forgetting over three months in asymptomatic APOE ε4 carriers. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 477-484.	3.7	7
212	Rapidly progressive dementia with psychotic onset in a patient with the C9ORF72 mutation. <i>Journal of Neurology</i> , 2015, 34, 294-297.		7
213	Data-driven staging of genetic frontotemporal dementia using multimodal MRI. <i>Human Brain Mapping</i> , 2022, 43, 1821-1835.	3.6	7
214	Brain tau expression and correlation with the H1/H1 tau genotype in frontotemporal lobar degeneration patients. <i>Journal of Neural Transmission</i> , 2007, 114, 1585-1588.	2.8	6
215	PSEN1 Mutation Carriers Present Lower Cerebrospinal Fluid Amyloid-β42 Levels than Sporadic Early-Onset Alzheimer's Disease Patients but no Differences in Neuronal Injury Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 605-616.	2.6	6
216	Novel P397S MAPT variant associated with late onset and slow progressive frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1559-1565.	3.7	6

#	ARTICLE	IF	CITATIONS
217	Errorless Learning Therapy in Semantic Variant of Primary Progressive Aphasia. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 415-422.	2.6	6
218	Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid positivity. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1037-1049.	2.7	6
219	Baseline MRI atrophy predicts 2-year cognitive outcomes in early-onset Alzheimer's disease. <i>Journal of Neurology</i> , 2022, 269, 2573-2583.	3.6	6
220	Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype. <i>Neurobiology of Aging</i> , 2016, 46, 169-179.	3.1	5
221	Adaptación y validación de la Frontotemporal Dementia Rating Scale (FTD-FRS) al castellano. <i>Neurología</i> , 2017, 32, 290-299.	0.7	5
222	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1065-1074.	2.6	5
223	Regional patterns of 18F-florbetaben uptake in presenilin 1 mutation carriers. <i>Neurobiology of Aging</i> , 2019, 81, 1-8.	3.1	5
224	Does ALS without <i>FUS</i> mutation represent ALS-FET? Report of three cases. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 421-426.	3.2	5
225	Use of Antipsychotics in Patients with Behavioral and Psychological Symptoms of Dementia: Results of a Spanish Delphi Consensus. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 573-582.	1.5	5
226	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, .	1.1	5
227	Evolution of Clinical-Pathological Correlations in Early-Onset Alzheimer's Disease Over a 25-Year Period in an Academic Brain Bank. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1659-1669.	2.6	5
228	New mutation in the PSEN1 (E120G) gene associated with early onset Alzheimer's disease. <i>Neurología (English Edition)</i> , 2010, 25, 13-16.	0.4	4
229	Focusing on atypical symptoms for improved diagnosis of early-onset Alzheimer's disease. <i>Future Neurology</i> , 2011, 6, 575-578.	0.5	4
230	Gerstmann-Sträussler-Scheinker Disease Presenting with Atypical Parkinsonism, but Typical Magnetic Resonance Imaging Findings of Prion Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 93-95.	1.5	4
231	Tauopathy with Hippocampal Repeat Tau Immunoreactive Spherical Inclusions in a Patient with PSP. <i>Brain Pathology</i> , 2018, 28, 284-286.	4.1	4
232	Sex Differences of Longitudinal Brain Changes in Cognitively Unimpaired Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1413-1422.	2.6	4
233	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
234	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	4



#	ARTICLE	IF	CITATIONS
235	Discrepancies in the Clinical Utility of the 14-3-3 Protein for the Diagnosis of Sporadic Creutzfeldt-Jakob Disease. <i>Archives of Neurology</i> , 2004, 61, 604.	4.5	3
236	Adaptation and validation of a Spanish-language version of the Frontotemporal Dementia Rating Scale (FTD-FRS). <i>Neurología (English Edition)</i> , 2017, 32, 290-299.	0.4	3
237	CSF-ApoER2 fragments as a read-out of reelin signaling: Distinct patterns in sporadic and autosomal-dominant Alzheimer disease. <i>Clinica Chimica Acta</i> , 2019, 490, 6-11.	1.1	3
238	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	3.1	3
239	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-14.	2.6	3
240	O4-11-04: ACTIVE A $\beta$ IMMUNOTHERAPY CAD106 PHASE II DOSE-ADJUVANT FINDING STUDY: SAFETY AND CNS BIOMARKERS. , 2014, 10, P274-P274.		2
241	[P4 $\beta$ 189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P1337.	0.8	2
242	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	2.4	2
243	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. <i>Alzheimer's and Dementia</i> , 0, , .	0.8	2
244	Bioenergetic and Autophagic Characterization of Skin Fibroblasts from C9orf72 Patients. <i>Antioxidants</i> , 2022, 11, 1129.	5.1	2
245	In vivo decreased dopamine transporter uptake in corticobasal degeneration presenting with primary progressive aphasia without parkinsonism. <i>European Journal of Neurology</i> , 2014, 21, e56-e57.	3.3	1
246	Pioglitazone for prevention of cognitive impairment: results and lessons. <i>Lancet Neurology</i> , The, 2021, 20, 500-502.	10.2	1
247	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 336-339.	1.9	1
248	Clinical Neuropathology image 4-2017: High-resolution 7 Tesla MRI of postmortem brain specimens: improving neuroimaging-neuropathology correlations. , 2017, 36, 162-163.		1
249	Homozygous R136S mutation in PRNP gene causes inherited early onset prion disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 176.	6.2	1
250	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
251	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. <i>Journal of Neurology</i> , 2022, 269, 4322-4332.	3.6	1
252	The <sc>CBI</sc> detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	3.7	1



#	ARTICLE	IF	CITATIONS
253	ALTOIDAâ€ADL for the diagnosis of Mild Cognitive Impairment and early Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, e057982.	0.8	1
254	Reply. Annals of Neurology, 2014, 75, 460-461.	5.3	0
255	O3-13-06: Targeted re-sequencing of sorl1 in early-onset Alzheimer's dementia: The european early onset dementia consortium. , 2015, 11, P253-P253.		0
256	IC-02-05: Cerebrospinal Fluid Strem2 Levels are Associated with Gray Matter Volume Increases and Reduced Diffusivity in Early Alzheimerâ€™s Disease. , 2016, 12, P8-P8.		0
257	[P4â€207]: A PRESCREENING STUDY IN SPAIN TO IDENTIFY INDIVIDUALS WHO MIGHT BE SUITABLE FOR PARTICIPATION IN CLINICAL STUDIES IN EARLY ALZHEIMER'S DISEASE UTILIZING REFERRALS FROM GENERAL PRACTITIONER NETWORKS. Alzheimer's and Dementia, 2017, 13, P1345.	0.8	0
258	[P2â€410]: VISUAL AND QUANTITATIVE ASSESSMENT OF HIPPOCAMPAL ATROPHY IN EARLY ONSET ALZHEIMER'S DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P789.	0.8	0
259	[P4â€214]: TOWARD A FUNCTIONAL NEUROMARKER FOR PRECLINICAL AD: EIGENVECTOR CENTRALITY REVEALS PRECLINICAL DIFFERENCES OF FUNCTIONAL INFORMATION FLOW IN THE HIPPOCAMPUS, PRECUNEUS, CEREBELLUM AND INFERIOR PARIETAL LOBULE. Alzheimer's and Dementia, 2017, 13, P1348.	0.8	0
260	[P1â€413]: VISUAL PATTERNS OF FLORBETABEN UPTAKE IN PRESENILIN 1 MUTATION CARRIERS. Alzheimer's and Dementia, 2017, 13, P435.	0.8	0
261	P2â€347: THE HIPPOCAMPAL LONGITUDINAL AXIS: RELEVANCE FOR UNDERLYING TAU AND TDPâ€43 PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P819.	0.8	0
262	P1â€146: WHOLE EXOME SEQUENCING IN PATIENTS WITH EARLYâ€ONSET ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA: MUTATION DETECTION IN CAUSAL AND RISK GENES FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, P332.	0.8	0
263	P2â€262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2018, 14, P777.	0.8	0
264	P3â€394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P1248.	0.8	0
265	P1â€432: REGIONAL PATTERNS OF 18Fâ€FLORBETABEN UPTAKE IN PRESENILIN 1â€MUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P475.	0.8	0
266	O3â€09â€03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1037.	0.8	0
267	P2â€230: CHALLENGES ASSOCIATED WITH BIOMARKERâ€BASED CLASSIFICATIONS SYSTEMS FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P756.	0.8	0
268	ICâ€02â€05: GENDER DIFFERENCES IN THE ASSOCIATION BETWEEN LONGITUDINAL BRAIN CHANGES AND BASELINE LEVELS OF CSF ALZHEIMER'S DISEASE AND GLIAL BIOMARKERS IN HEALTHY ELDERS. Alzheimer's and Dementia, 2019, 15, P4.	0.8	0
269	Functional network alterations in earlyâ€onset Alzheimerâ€™s disease studied with restingâ€state fMRI. Alzheimer's and Dementia, 2020, 16, e043307.	0.8	0
270	Prion diseases. European Neuropsychopharmacology, 2022, 55, 1-3.	0.7	0

#	ARTICLE	IF	CITATIONS
271	Assessment of Cognitive Symptoms in Brain Bank-Registered Control Subjects: Feasibility and Utility of a Telephone-Based Screening. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1107-1113.	2.6	0
272	Detecting clinical progression from abnormal regional brain volumes at baseline in genetic frontotemporal dementia: A GENFI study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
273	Agreement of amyloid PET and CSF biomarkers in a clinical cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
274	A data-driven disease progression model of fluid biomarkers in genetic FTD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
275	Impact of COVID-19 pandemic in an early-onset dementia clinic in Barcelona. <i>Alzheimer's and Dementia</i> , 2021, 17, e052114.	0.8	0
276	Atrophy patterns in sporadic and genetic behavioral variant frontotemporal dementia reflect brain network architecture. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
277	The location of <i>PSEN1</i> pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0